Straits Times Index
3,258.26 -41.78 (-1.27%) Nikkei
38,202.37 -632.73 (-1.63%) Hang Seng
18,322.55 -156.82 (-0.85%) FTSE 100
8,347.12 +33.45 (+0.40%) Bitcoin USD
62,218.41 -1,284.96 (-2.02%) CMC Crypto 200
1,292.43 -2.24 (-0.17%)
The Trendlines Group Ltd. (42T.SI)
| Previous close | 0.0650 |
| Open | 0.0650 |
| Bid | 0.0650 x 0 |
| Ask | 0.0660 x 0 |
| Day's range | 0.0650 - 0.0650 |
| 52-week range | 0.0620 - 0.1050 |
| Volume | |
| Avg. volume | 278,045 |
| Market cap | 62.407M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
ZygoFix Receives FDA Clearance for its zLOCK Lumbar Facet Fixation System
ZygoFix Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") announced that it received regulatory clearance from the United States Food and Drug Administration (FDA clearance) for its zLOCK Lumbar Facet Fixation System. This achievement was supported by compelling clinical evidence from the company's ongoing European clinical study, marking a significant advancement in spinal fusion technology.
- PR Newswire
Arcuro Medical Appoints Jamal Rushdy CEO
Arcuro Medical Ltd. (www.arcuromedical.com), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), today announced the appointment of MedTech industry veteran Jamal Rushdy as Chief Executive Officer.
- PR Newswire
Vessi Medical Closes $16.5 Million Series A Round for Innovative Cryotherapy Bladder Cancer Treatment
Vessi Medical Ltd. ("Vessi") announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer ("NMIBC"). Leading investors in the round are an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary, joining The Trendlines Group.
